Larimar Therapeutics, Inc. (LRMR) has released an update.
On February 12, 2024, the company revealed positive outcomes from its Phase 2 study of nomlabofusp for treating Friedreich’s ataxia, sharing the news through a press release and updating their investor presentations online. The results, marking the trial’s successful completion, are anticipated to generate interest and discussions in upcoming meetings with investors and analysts.
For further insights into LRMR stock, check out TipRanks’ Stock Analysis page.
